CareDx Non-GAAP EPS of $0.70 beats by $0.44, revenue of $139M beats by $17.04M (NASDAQ:CDNA)
CareDx reported Q3 Non-GAAP EPS of $0.70, exceeding estimates by $0.44, and revenue of $139M, up 39.0% year-over-year and $17.04M above expectations. The company raised its 2026 revenue guidance to $520M-$530M.
How this was made
The 30-second read
Why it matters
The earnings beat and raised guidance could trigger a short‑term rally, but investors should monitor guidance sustainability.
Market read
First‑report earnings release with material beat; high relevance for traders.
What to watch
Potential headwinds from reimbursement policy changes and competitive pressure.
Background
CareDx is a U.S. listed molecular diagnostics company focused on transplant monitoring.
Ticker impact
CareDx reported Q3 Non‑GAAP EPS of $0.70 beating estimates by $0.44 and revenue of $139 M beating by $17.04 M, with FY2026 revenue guidance raised to $520‑$530 M.
likely upward as investors price in the earnings beat and higher revenue outlook
Both EPS and revenue exceeded expectations and guidance was increased, providing a clear catalyst for short‑term buying.
Market effects
Positive signal for the molecular diagnostics sector, may lift peers.
U.S. biotech market may see modest gains.
Limited to healthcare investors, no broad market effect.
Counterpoint
If the beat is already priced in, the stock could face a pull‑back.
Key entities
- CompanyCareDx, Inc.
Provider of diagnostic testing services.
